SCHEMBL5493433

SCHEMBL5493433

Clc1ccccc1/C=C/c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHAT P28329 1/20 0.66
NFE2L2 Q16236 4/20 0.63
CYP1A2 P05177 2/20 0.63
CYP1A1 P04798 1/20 0.63
CYP1B1 Q16678 1/20 0.63
RELA Q04206 1/20 0.63
TRPA1 O75762 2/20 0.56
ALDH1A1 P00352 3/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493438 1.00 CHAT (0.66) CHATNFE2L2CYP1A2CYP1A1CYP1B1
SCHEMBL1058814 0.87 ALDH1A1 (0.62) CHATNFE2L2CYP1A2CYP1A1CYP1B1
SCHEMBL9586694 0.87 ALDH1A1 (0.62) CHATNFE2L2CYP1A2CYP1A1CYP1B1
SCHEMBL699770 0.86 NFE2L2 (0.66) CHATNFE2L2CYP1A2CYP1A1CYP1B1
SCHEMBL11319367 0.86 MAOB (0.61) CHATNFE2L2CYP1A2CYP1A1CYP1B1
SCHEMBL699771 0.86 NFE2L2 (0.66) CHATNFE2L2CYP1A2CYP1A1CYP1B1
SCHEMBL11319372 0.86 MAOB (0.61) CHATNFE2L2CYP1A2CYP1A1CYP1B1
Anisole SCHEMBL29005748 0.85 NFE2L2 (0.84) CHATNFE2L2CYP1A2CYP1A1CYP1B1
Benzoic Acid SCHEMBL20968924 0.85 TTR (0.56) CHATNFE2L2CYP1A2CYP1A1CYP1B1
Water SCHEMBL22130353 0.85 ALDH1A1 (0.59) CHATNFE2L2CYP1A2CYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710510-B1 PROCESS FOR PREPARING POLYCARBONATE AND CATALYTIC SYSTEM USED ENI SPA (IT) 2021-09-22 EP claimed
CN-102001949-A 3,5-dimethoxystilbene derivative, preparation method and application thereof in anti-drug resistant bacteria UNIV SOUTH CHINA TECH 2011-04-06 CN claimed
EP-0203606-B1 DERIVATIVES OF STILBENE AND FUNGICIDES CONTAINING THESE COMPOUNDS BASF Aktiengesellschaft (DE) 1990-10-31 EP claimed
EP-3527593-B1 ISOCYANATE COMPOSITION, METHOD FOR PRODUCING ISOCYANATE COMPOSITION, AND METHOD FOR PRODUCING ISOCYANATE POLYMER ASAHI CHEMICAL IND (JP) 2025-07-23 EP disclosed
EP-3527600-B1 ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER ASAHI CHEMICAL IND (JP) 2025-07-09 EP disclosed
CN-117625071-A Light conversion adhesive film, preparation method thereof and perovskite battery packaging structure 广东明阳薄膜科技有限公司 2024-03-01 CN disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
US-20230234900-A1 METHODS OF ARENE ALKENYLATION UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2023-07-27 US disclosed
CN-112979917-B Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer 旭化成株式会社 2023-04-25 CN disclosed
US-20230114799-A1 ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-04-13 US disclosed
CN-85107531-A Process for producing vinyl chloride polymer 1987-01-21 CN disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed
EP-0024567-A1 2-(4-Aminobutoxy)stilbenes and pharmaceutical compositions comprising these compounds MITSUBISHI KASEI CORPORATION (JP) 1981-03-11 EP disclosed
US-4094606-A Xerographic system employing waveguide addressing and modulating apparatus XEROX CORPORATION (US) 1978-06-13 US disclosed
US-4077700-A Waveguide addressing and modulating method and apparatus XEROX CORPORATION (US) 1978-03-07 US disclosed
US-4005032-A Liquid crystalline composition having mixed cholesteric-nematic properties XEROX CORPORATION (US) 1977-01-25 US disclosed
US-3989355-A Electro-optic display system XEROX CORPORATION (US) 1976-11-02 US disclosed
US-3947183-A LIQUID CRYSTAL DISPLAY SYSTEM XEROX CORPORATION (US) 1976-03-30 US disclosed
US-3932026-A Liquid crystal display assembly having dielectric coated electrodes INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234900-A1 METHODS OF ARENE ALKENYLATION CYBB, CBR3, AHR CHAT 1290/4885NFE2L2 102/4885CYP1A2 255/4885
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB CHAT 3676/4885NFE2L2 1434/4885CYP1A2 3735/4885
US-20230114799-A1 ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER IDH3A, IDH2, IDH3B CHAT 718/4885NFE2L2 1150/4885CYP1A2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.